Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2002 1
2009 2
2011 1
2012 3
2013 5
2014 8
2015 4
2016 2
2017 8
2018 5
2019 3
2020 1
2021 6
2022 7
2023 15
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Cummings SR, et al. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. N Engl J Med. 2009. PMID: 19671655 Free article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Endothelial dysfunction in patients with ankylosing spondylitis.
Łosińska K, Korkosz M, Kwaśny-Krochin B. Łosińska K, et al. Among authors: korkosz m. Reumatologia. 2019;57(2):100-105. doi: 10.5114/reum.2019.84815. Epub 2019 Apr 29. Reumatologia. 2019. PMID: 31130748 Free PMC article. Review.
SARS-CoV-2 infection impairs NK cell functions via activation of the LLT1-CD161 axis.
Lenart M, Górecka M, Bochenek M, Barreto-Duran E, Szczepański A, Gałuszka-Bulaga A, Mazur-Panasiuk N, Węglarczyk K, Siwiec-Koźlik A, Korkosz M, Łabaj PP, Baj-Krzyworzeka M, Siedlar M, Pyrc K. Lenart M, et al. Among authors: korkosz m. Front Immunol. 2023 May 23;14:1123155. doi: 10.3389/fimmu.2023.1123155. eCollection 2023. Front Immunol. 2023. PMID: 37287972 Free PMC article.
Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R, Kosałka-Węgiel J, Kuszmiersz P, Mituś JW, Püsküllüoğlu M, Grela-Wojewoda A, Korkosz M, Bazan-Socha S. Pacholczak-Madej R, et al. Among authors: korkosz m. Int J Environ Res Public Health. 2023 Mar 10;20(6):4926. doi: 10.3390/ijerph20064926. Int J Environ Res Public Health. 2023. PMID: 36981837 Free PMC article. Review.
80 results